My research interests focus on improving the care of women with breast cancer through clinical trials. I lead a spectrum of clinical studies spanning the spectrum of the disease and ranging from phase I to randomised phase III. The majority of these studies are translational phase II studies investigating novel targeted and immune therapies. Our current interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in breast cancer).
Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med (2020) 382(9):810-821. PMID: 32101663
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet (2020) 396(10265):1817-1828. PMID: 33278935
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2020) 21(1):44-59. PMID: 31786121
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med (2018) 379(22):2108-2121. PMID: 30345906
Professor Schmid’s research is focused on improving the care of women with breast cancer through clinical trials. He is investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue. Professor Schmid runs an international clinical and translational research programme spanning the spectrum of the disease and ranging from phase I to randomised phase III. The majority of the studies incorporate translational research endpoints to improve our understanding of molecular factors that may elucidate mechanisms of action and predictors of treatment effect; this includes a programme on the impact of the microbiome on patient outcomes.
His current research interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in breast cancer).
Professor Schmid is the lead investigator of several international, pivotal breast cancer studies on novel targeted therapeutics to improve the treatment of both early and late stage breast cancer. He was the lead investigator of the Impassion130 trial that evaluated atezolizumab for advanced triple-negative breast cancer and lead to the approval of the first immunotherapy strategy for patients with breast cancer, establishing a new standard of care for this disease. He was also the lead investigator of the KEYNOTE-522 trial which established the addition of the immune-checkpoint inhibitor Pembrolizumab to preoperative chemotherapy as a new standard for patients with stage II or III triple-negative breast cancer based on a 37% reduction in recurrences of this aggressive subtype of breast cancer.
Professor Schmid’s work has published over 100 peer-reviewed papers in medical journals, including the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Communications and the Journal of Clinical Oncology. He has grant income from national and international funding bodies.
Prof Schmid is a member of several national and international cancer organisations and research groups. He has been involved in international consensus meetings and is co-author of international guidelines on the management of breast cancer. Professor Peter Schmid is Chair of the European Society for Medical Oncology (ESMO) breast cancer faculty and he is part of the faculty for the major global oncology meetings.
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis Cortes J, Haiderali A, Huang M et al. BMC Cancer (2023) 23(7)
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease Schmid P, Cortes J, Joaquim A et al. Breast Cancer Research (2023) 25(7)
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Tarantino P, Viale G, Press MF et al. Annals of Oncology (2023) 34(7) 645-659
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy Reinisch M, Bruzas S, Gluz O et al. Molecular Oncology (2023) 17(7) 1060-1075
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study Oswald AJ, Symeonides SN, Wheatley D et al. Breast Cancer Research and Treatment (2023) 199(7) 35-46
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer Rudin CM, Cervantes A, Dowlati A et al. ESMO Open (2023) 8(7)
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer Turner NC, Swift C, Jenkins B et al. Annals of Oncology (2023) 34(7) 200-211
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial Di Cosimo S, Pérez-García JM, Bellet M et al. The oncologist (2023) 28(7) 23-32
Evaluation of triple negative breast cancer with heterogeneous immune infiltration Quintana Á, Arenas EJ, Bernadó C et al. Frontiers in Immunology (2023) 14(7)
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC de Castro G, Rizvi NA, Schmid P et al. Journal of Thoracic Oncology (2023) 18(7) 106-119For additional publications, please click here
Professor Schmid is the clinical director of the Breast Cancer Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He was appointed in 2013 as Chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University London. Professor Schmid is the Lead of the Centre of Experimental Cancer Medicine at BCI, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI. He leads the academic breast cancer programme at St. Bartholomew’s Hospital and BCI.
Professor Schmid trained in medicine in Munich and Aberdeen. He was awarded scholarships by the 'Studienstiftung des deutschen Volkes' (German Academic Scholarship Foundation), the 'Hanns-Seidel-Foundation', and the 'Deutscher Akademischer Austauschdienst' (German Academic Exchange Service). He graduated from the Technical University of Munich medical school in 1997, gaining a MD in Clinical Chemistry in 1998 from the University of Munich and a Clinical Research PhD in 2005 from Charité University in Berlin.
Prof Schmid trained at the University Hospital Charité in Berlin in internal medicine, haematology, and oncology, before he became a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London in 2005. Professor Schmid was appointed as Foundation Chair in Cancer Medicine at the University of Sussex in 2010, before taking on his current role at BCI in 2013.